🚨Our March issue is LIVE🚨 Learn about immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics in our cover profile🔷 Sourcing, nurturing, and retaining talent🔷Making HCP analytics actually work for commercial teams🔷and much more right here➡️pharmexec.com/journals/pharm…

Sustainability, precision, and real-time monitoring are redefining pharma logistics—ensuring safe, efficient delivery of temperature-sensitive therapies worldwide. #PharmaLogistics hubs.li/Q04f83tC0

New Series Alert: Profits & Pipelines 📈 This bi-weekly YouTube series breaks down pharma stock performance and the business developments behind the numbers. ➡️ Watch the first episode: hubs.li/Q04kPqd50 #ProfitsAndPipelines #PharmExec #PharmaIndustry #HealthcareInvesting

🚨 PE Spotlight: $43B in pharma deals with China in just five months. Pharma isn't just licensing molecules. It's co-authoring drug discovery with Chinese partners. What's driving it, what do the deals look like, and what legal risks come after signing? 🔗Unlock more: hubs.li/Q04kKCzw0 #PharmExec #Biopharma

In today’s volatile pharma landscape, resilient supply chain partnerships depend on trust, transparency, and strong cross-functional collaboration to keep patients at the center of every decision. #SupplyChain hubs.li/Q04jlR0Q0

We asked David Hung of Nuvation Bio one question about filming at MJH Studios. Watch his answer. 📽️ If you want to: ✅ Experience a state-of-the-art studio ✅ Walk away genuinely impressed ✅ Tell your story the right way If you have a chance to come on-site, take it. You won't be disappointed. #PharmaceuticalExecutive #Pharma #Leadership

🎥 A great morning in the MJH Life Sciences studio with David Hung, M.D. Nicholas Jacobus of Pharm Exec sat down with the founder, president, and CEO of Nuvation Bio to discuss leadership, innovation, and what's next for the company. Stay tuned for more behind-the-scenes content and the full interview coming soon. #PharmExec #Oncology #HealthcareLeadership

Can stricter oversight of DTC prescription drug ads survive First Amendment scrutiny? Dan Troy, former chief counsel for the FDA, discusses the legal hurdles facing efforts to increase regulation of pharmaceutical advertising. Watch the interview: hubs.li/Q04jYcpj0 #Pharma #FDA

What makes social media worth your time? Share your perspective and help shape the content you see on social media. Take the survey: hubs.li/Q04jQBLb0 #IndustryScienceOne #SocialMediaStrategy

Are GLP-1s changing the pharma playbook? Kevin Dondarski of Deloitte Consulting explains how GLP-1s becoming major value drivers signals a broader strategic shift for the industry. Watch more: hubs.li/Q04jDr-Z0 #Pharma #GLP1

What would a stronger FDA-biopharma relationship look like? Harpreet Singh, MD, chief medical officer at Precision for Medicine and former FDA Oncology Division Director, shares her perspective. 👉Watch the full interview: hubs.li/Q04jb7V-0 #FDA #Biopharma #PharmExec

Flexible, scalable hub strategies are becoming essential as patient support programs evolve—helping manufacturers adapt faster, improve access, and deliver better patient experiences. #PatientSupport hubs.li/Q04gpmk90

Your SEO strategy may not be enough anymore. AI search is now summarizing healthcare content into single answers, shaping patient and HCP perception instantly. When those answers are incomplete or misaligned, the risk isn’t just traffic loss it’s clinical, regulatory, and reputational impact. In this upcoming webinar, learn how to: ✔ Understand how AI-generated answers are formed ✔ Strengthen content structure and evidence signals ✔ Improve accuracy and visibility in AI search results ✔ Track AI visibility beyond traditional metrics Register here:hubs.li/Q04fTl6x0

Cardinal Health is advancing biopharma logistics with integrated 3PL services, expanded cold chain capabilities, and faster speed-to-patient solutions designed for today’s complex supply chain demands. #PharmaLogistics hubs.li/Q04g8xJY0

🚨 PE Spotlight: Rewiring oncology operations at scale. John Oyler of BeOne Medicines shares how the company is rethinking development speed, clinical execution, and global manufacturing strategy. Explore the full feature: hubs.li/Q04hH0LN0 #PharmExec #PEspotlight #Oncology #Pharma

Did you know? The FDA has approved baxdrostat for uncontrolled hypertension, adding a new option for patients whose blood pressure remains difficult to manage on existing therapies. 🔗 Explore more: hubs.li/Q04h1KZ_0 #Pharma #FDA #Hypertension

A new all-oral treatment option for AML has entered the FDA-approved landscape. The FDA approved Inqovi in combination with venetoclax as the first and only all-oral combination treatment regimen for certain patients with acute myeloid leukemia. #Pharma #AML #FDA

Explore how ACTO is elevating sales effectiveness across life sciences—empowering over 50,000 field professionals to deliver confident, compliant HCP interactions. From global pharma leaders to emerging biotech, discover strategies driving field excellence: hubs.li/Q04c1q4G0 #LifeSciences

AI search is reshaping how healthcare brands get discovered. Join Victoria Houston and Mark Traphagen to learn: • How AI Overviews shape patient HCP discovery • Why brand content gets misrepresented in AI answers • The SEO signals that influence what AI surfaces • How to track and improve AI visibility at scale Register here:hubs.li/Q04fSk_W0

Sustainability, safety, and precision are redefining pharma logistics—innovations in cold chain and last-mile delivery are ensuring therapies reach patients reliably and responsibly. #PharmaLogistics hubs.li/Q04dYk7p0

🚨 PE Spotlight: Bringing Hepatitis B innovation to scale in China GSK teams up with SBP Group’s CTTQ unit to support Bepirovirsen’s launch across 5,000 medical centers in mainland China. 🔗 Read more: hubs.li/Q04gcMPd0 #PharmExec #PESpotlight #HepatitisB #Biotech #DrugDevelopment